Tags

Type your tag names separated by a space and hit enter

Chemerin as a marker of body fat and insulin resistance in women with polycystic ovary syndrome.
Gynecol Endocrinol 2015; 31(2):152-5GE

Abstract

Adipocytokines may alter normal metabolic function and play an important role in the pathophysiology of polycystic ovary syndrome (PCOS). We prospectively evaluated a cohort of obese and non-obese women with PCOS and non-PCOS controls for both novel (chemerin and omentin-1) and established (leptin and adiponectin) adipokines. Compared with age-matched controls, non-obese women with PCOS had decreased serum omentin-1 (191.1 ng/ml versus 269.7 ng/ml, p = 0.0001), while serum chemerin was not significantly altered in women with PCOS (53.95 ng/ml versus 48.61 ng/ml, p = 0.11). The findings were similar in the entire group of women with PCOS. However, in women with PCOS, chemerin correlated with leptin (r = 0.508, p = 0.004), adiponectin (r = -0.36, p = 0.014), and the leptin/adiponectin (L/A) ratio (r = 0.605, p < 0.0001), while there were no such correlations with omentin-1. In women with PCOS, chemerin correlated with BMI (r = 0.317, p = 0.034), abdominal subcutaneous fat (r = 0.451, p = 0.0019), and insulin resistance (HOMA-IR, r = 0.428, p = 0.0034), while omentin-1 did not correlate with any parameter. These data suggest that chemerin although not significantly elevated in women with PCOS correlates with adiposity and insulin resistance, and it is the single best adipokine measured in this regard. Chemerin, through its inflammatory role as a chemo-attractant in adipose tissue, may be an important determinant of insulin resistance in PCOS.

Authors+Show Affiliations

Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, Columbia University College of Physicians and Surgeons , New York, NY , USA.No affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25295622

Citation

Kort, Daniel H., et al. "Chemerin as a Marker of Body Fat and Insulin Resistance in Women With Polycystic Ovary Syndrome." Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, vol. 31, no. 2, 2015, pp. 152-5.
Kort DH, Kostolias A, Sullivan C, et al. Chemerin as a marker of body fat and insulin resistance in women with polycystic ovary syndrome. Gynecol Endocrinol. 2015;31(2):152-5.
Kort, D. H., Kostolias, A., Sullivan, C., & Lobo, R. A. (2015). Chemerin as a marker of body fat and insulin resistance in women with polycystic ovary syndrome. Gynecological Endocrinology : the Official Journal of the International Society of Gynecological Endocrinology, 31(2), pp. 152-5. doi:10.3109/09513590.2014.968547.
Kort DH, et al. Chemerin as a Marker of Body Fat and Insulin Resistance in Women With Polycystic Ovary Syndrome. Gynecol Endocrinol. 2015;31(2):152-5. PubMed PMID: 25295622.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Chemerin as a marker of body fat and insulin resistance in women with polycystic ovary syndrome. AU - Kort,Daniel H, AU - Kostolias,Alessandra, AU - Sullivan,Chantae, AU - Lobo,Roger A, Y1 - 2014/10/08/ PY - 2014/10/9/entrez PY - 2014/10/9/pubmed PY - 2015/10/2/medline KW - Body Mass Index KW - insulin resistance KW - polycystic ovary syndrome SP - 152 EP - 5 JF - Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology JO - Gynecol. Endocrinol. VL - 31 IS - 2 N2 - Adipocytokines may alter normal metabolic function and play an important role in the pathophysiology of polycystic ovary syndrome (PCOS). We prospectively evaluated a cohort of obese and non-obese women with PCOS and non-PCOS controls for both novel (chemerin and omentin-1) and established (leptin and adiponectin) adipokines. Compared with age-matched controls, non-obese women with PCOS had decreased serum omentin-1 (191.1 ng/ml versus 269.7 ng/ml, p = 0.0001), while serum chemerin was not significantly altered in women with PCOS (53.95 ng/ml versus 48.61 ng/ml, p = 0.11). The findings were similar in the entire group of women with PCOS. However, in women with PCOS, chemerin correlated with leptin (r = 0.508, p = 0.004), adiponectin (r = -0.36, p = 0.014), and the leptin/adiponectin (L/A) ratio (r = 0.605, p < 0.0001), while there were no such correlations with omentin-1. In women with PCOS, chemerin correlated with BMI (r = 0.317, p = 0.034), abdominal subcutaneous fat (r = 0.451, p = 0.0019), and insulin resistance (HOMA-IR, r = 0.428, p = 0.0034), while omentin-1 did not correlate with any parameter. These data suggest that chemerin although not significantly elevated in women with PCOS correlates with adiposity and insulin resistance, and it is the single best adipokine measured in this regard. Chemerin, through its inflammatory role as a chemo-attractant in adipose tissue, may be an important determinant of insulin resistance in PCOS. SN - 1473-0766 UR - https://www.unboundmedicine.com/medline/citation/25295622/Chemerin_as_a_marker_of_body_fat_and_insulin_resistance_in_women_with_polycystic_ovary_syndrome_ L2 - http://www.tandfonline.com/doi/full/10.3109/09513590.2014.968547 DB - PRIME DP - Unbound Medicine ER -